Daewoong Pharmaceutical is accelerating global training programs for Nabota partners as the Korean botulinum toxin brand expands into new markets. The company projects Nabota sales will reach ₩300 billion this year, signaling confidence in its competitive position outside North America and Western Europe, where Allergan Aesthetics dominates.
Injectables
Daewoong Ramps Nabota Training Ahead of Global Push
South Korea's toxin maker is scaling partner education as it targets market share outside AbbVie's core geographies.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Nabota sales projected to hit ₩300 billion this year as Daewoong trains global partners.
Nabota is a proprietary formulation with a different manufacturing process than Botox or Dysport, which can affect onset, duration, and diffusion profiles. Practitioners unfamiliar with the product need structured education on dosing and patient selection to avoid poor outcomes and protect the brand's reputation. Daewoong's investment in partner training suggests it is betting on geographic expansion—likely Southeast Asia, India, and emerging markets where pricing pressure and regulatory pathways favor new entrants over incumbents.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.